对YAP和TAZ在癌症中的最新发现和临床应用的见解

2023-06-30 10:25

在这篇综述中，我们的目标是以一个综合的视角来总结许多关于YAP和TAZ在癌症中的不同发现。然后，我们总结了靶向和治疗YAP和TAZ依赖癌症的各种策略。

SCI 29 June 2023

Insights into recent findings and clinical application of YAP and TAZ in cancer

(Nature reviews. Cancer, IF: 69.800)

Franklin JM, Wu Z, Guan KL. Insights into recent findings and clinical application of YAP and TAZ in cancer. Nat Rev Cancer. 2023 Jun 12. doi: 10.1038/s41568-023-00579-1. Epub ahead of print. PMID: 37308716.

Corresponding author: Kun-Liang Guan, Department of Pharmacology and Moores Cancer Center, University of California San Diego, La Jolla, CA, USA. e-mail: kuguan@ucsd.edu

Abstract

Decades of research have mapped out the basic mechanics of the Hippo pathway. The paralogues Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ), as the central transcription control module of the Hippo pathway, have long been implicated in the progression of various human cancers. The current literature regarding oncogenic YAP and TAZ activities consists mostly of context-specific mechanisms and treatments of human cancers. Furthermore, a growing number of studies demonstrate tumour-suppressor functions of YAP and TAZ. In this Review we aim to synthesize an integrated perspective of the many disparate findings regarding YAP and TAZ in cancer. We then conclude with the various strategies for targeting and treating YAP- and TAZ-dependent cancers.

几十年的研究已经弄清了Hippo通路的基本机制。旁系同源基因YAP和带有PDZ结合序列的转录共激活因子(TAZ)作为Hippo通路的中央转录调控模块，长期以来一直与多种人类癌症的进展有关。目前关于致癌的YAP和TAZ活性的文献主要包括人类癌症的特定背景机制和治疗。此外，越来越多的研究表明YAP和TAZ具有肿瘤抑制功能。在这篇综述中，我们的目标是以一个综合的视角来总结许多关于YAP和TAZ在癌症中的不同发现。然后，我们总结了靶向和治疗YAP和TAZ依赖癌症的各种策略。